Study of a new drug for advanced solid tumors in women
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug, AZD8421, alone or with other treatments, for women with advanced solid tumors that have not responded to prior therapies. It aims to find a safe dose and see if it can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have an advanced solid tumor that has spread or come back, and standard treatments have stopped working or are not an option.
- Your cancer has grown despite your last treatment.
- You are able to take care of yourself (ECOG score 0 or 1) and expected to live at least 12 weeks.
- You have at least one tumor that can be measured or seen on scans.
- You must not have had certain cancer treatments or major surgery within the past few weeks, and you must be willing to avoid specific medications and pregnancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IMP1734 for people with advanced breast, ovarian, or prostate cancer that has a specific genetic change called an HRR mutation. The drug targets a protein called PARP1 to try to stop cancer cells from repairing themselves.
This Phase 1/2 study tests how safe and effective AZD8205 is for people with advanced or metastatic solid cancers that have come back or spread after standard treatments. It may help by finding the right dose and whether AZD8205 works alone or with another treatment in different cancer types.
This trial tests a new drug (GRWD5769) that may help your immune system fight cancer. It is for people with advanced solid tumors that have stopped responding to standard treatments, including certain types of cervical, liver, and other cancers.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This trial tests an experimental drug called Saruparib in people with advanced solid tumors that haven't responded to standard treatments. The study will see how the drug is absorbed, distributed, and eliminated from the body.
This trial is testing a new drug called ECI830, either alone or with another drug, for people with advanced breast cancer or other solid tumors that have not responded to standard treatments. It may be an option if you have HR+/HER2- breast cancer, small cell lung cancer, or a tumor with a specific gene change (CCNE1 amplification).
Hear when a new ER+ HER2- Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.